1,2-Diaza-7,8-benzazulen | 229-46-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1,2-Diaza-7,8-benzazulen
• 英文别名: 3,4-Diazatricyclo[8.4.0.02,6]tetradeca-1(14),2,4,6,8,10,12-heptaene
• CAS: 229-46-9
• 化学式: C₁₂H₈N₂
• 分子量: 180.209
• InChiKey: MTZUUVVAFDYPHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands
  申请人：——

  公开号：US20040058970A1

  公开（公告）日：2004-03-25

  The present invention relates to compounds of formula I: 1 in which R 1 is a linear group or a five membered heterocycle optionally fused to a phenyl ring, R 2 is a 5-membered heterocycle, R 3 is chosen from a range of substituents, m is 0-3 and n is 0 or 1; the compounds are generally inverse agonists at GABA-A receptors containing the alpha 5 subunit and so are useful in methods of enhancing cognition in subjects with diminished cognition in diseases such as Alzheimer's Disease.

  本发明涉及式I的化合物：其中R1是线性基团或者一个五元杂环，可选择地与苯环融合，R2是一个五元杂环，R3是从一系列取代基中选择的，m为0-3，n为0或1；这些化合物通常是GABA-A受体中含有α5亚基的逆激动剂，因此在增强认知的方法中对患有认知减退症如阿尔茨海默病的受试者是有用的。
• Noncardiotoxic pharmaceutical compounds
  申请人：Barbeau L. Donald

  公开号：US20060035863A1

  公开（公告）日：2006-02-16

  The present invention relates to novel noncardiotoxic compounds and pharmaceutical compositions useful in the treatment of a variety of disorders including the treatment of depression, allergies, psychoses, cancer and gastrointestinal disorders. In particular, the present invention describes pharmaceutical compositions that mitigate life-threatening arrhythmias such as torsade de pointes. Torsade de pointes is a particular cardiac problem associated with many therapeutic agents and has been implicated as a possible cause of sudden death, particularly in those individuals with a past history of disturbances of cardiac rhythm, myocardial infarction, congenital repolarization abnormalities and cardiac risk factors such as hyperlipidemia and age. This arrhythmia is a variant of paroxysmal ventricular tachycardia associated with a prolonged QTc interval or prominent U waves on the ECG. Torsade de pointes is potentially lethal because it can progress to ventricular fibrillation, life-threatening arrhythmias or precipitate sudden death.

  本发明涉及新型无心脏毒性化合物和药物组合物，用于治疗包括抑郁症、过敏、精神病、癌症和胃肠道疾病在内的各种疾病。具体而言，本发明描述了可以缓解危及生命的心律失常，例如扭转型尖波。扭转型尖波是与许多治疗剂相关的一种特殊心脏问题，已被指认为可能导致猝死的原因，特别是在那些有心脏节律紊乱、心肌梗死、先天性复极异常和心脏危险因素（如高脂血症和年龄）的个体中。这种心律失常是一种与心电图上QTc间期延长或U波显著的室性心动过速变异有关的心律失常。扭转型尖波有潜在致命性，因为它可能发展为室颤、危及生命的心律失常或引发猝死。
• Isoxazole pyrazoloindane derivatives as cognition enhancing GABA-A alpha 5 subtype ligands
  申请人：——

  公开号：US20040006226A1

  公开（公告）日：2004-01-08

  The present invention provides compounds of formula I: 1 in which: one of X and Y is a nitrogen atom substituted by a group R 6 ′ and the other is a carbon atom substituted by an isoxazole group substituted on its carbon atoms by groups R 3 and R 4 ; one of R 6 and R 6 ′ is hydrogen; either all of W 1 , W 2 , W 3 and W 4 are carbon or one of W 1 , W 2 , W 3 and W 4 is nitrogen and the rest are carbon; and R 1 and R 2 are, independently, a small group, heteroaromatic ring or a 4-7 membered cyclic amine ring; processes for making them; pharmaceutical composition containing them; their use in therapy, particularly for enhancing cognition in conditions such as Alzheimer's Disease; and methods of treatment using them.

  本发明提供了化合物的公式I：其中：X和Y中的一个是由基团R6′取代的氮原子，另一个是由异唑啉基团取代的碳原子，其碳原子上取代有基团R3和R4；R6和R6′中的一个是氢；W1、W2、W3和W4中的所有或其中一个是氮，其余为碳；R1和R2分别是小基团、杂环芳香环或4-7成员环胺基；制备它们的方法；含有它们的药物组合物；它们在治疗中的应用，特别是在增强认知方面，如阿尔茨海默病等情况；以及使用它们的治疗方法。
• [EN] BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE<br/>[FR] COMPOSÉS DE BENZOXAZÉPINE SÉLECTIFS POUR PI3K P110 DELTA ET LEURS MÉTHODES D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012126901A1

  公开（公告）日：2012-09-27

  Benzoxazepin Formula (I) compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  BenzoxazePIn Formula (I) 化合物，包括立体异构体、几何异构体、互变异构体、代谢物和药学上可接受的盐，对于抑制PI3K的δ异构体以及治疗由脂质激酶介导的炎症、免疫性疾病和癌症是有用的。本文还揭示了使用Formula (I) 化合物在哺乳动物细胞中进行体外、体内和原位诊断、预防或治疗此类疾病或相关病理情况的方法。
• [EN] BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE BENZOXAZÉPINE INHIBITEURS DE PI3K ET LEURS PROCÉDÉS D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011036280A1

  公开（公告）日：2011-03-31

  The invention relates to benzoxazepin compounds of Formula (I) including stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring which compounds have anti-cancer activity, and more specifically, inhibit PI3 kinase activity.

  本发明涉及公式（I）的苯并噁唑烷化合物，包括立体异构体，几何异构体，互变异构体或其药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；B为吡唑基，咪唑基或三唑基环，这些化合物具有抗癌活性，更具体地抑制PI3激酶活性。